SCHEMBL972345

SCHEMBL972345

COc1ccc(Cn2cnnn2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
CYP1A2 P05177 1/20 0.60
CYP2C9 P11712 1/20 0.60
MAPT P10636 2/20 0.51
TP53 P04637 1/20 0.51
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
GSK3A P49840 1/20 0.49
GSK3B P49841 1/20 0.49
KDM4E B2RXH2 2/20 0.48
MAPK1 P28482 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
ALDH1A1 P00352 3/20 0.47
ALOX15 P16050 1/20 0.47
CMA1 P23946 1/20 0.47
HSP90AA1 P07900 1/20 0.46
HSP90AB1 P08238 1/20 0.46
CYP19A1 P11511 2/20 0.44
SIGMAR1 Q99720 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10066409 0.82 MEN1 (0.54) MEN1KMT2ACYP1A2CYP2C9MAPT
SCHEMBL10053477 0.80 MEN1 (0.53) MEN1KMT2ACYP1A2CYP2C9MAPT
SCHEMBL22397991 0.80 TP53 (0.52) MEN1KMT2ACYP1A2CYP2C9MAPT
SCHEMBL187941 0.79 KMT2A (0.76) MEN1KMT2ACYP1A2CYP2C9KDM4E
SCHEMBL23913862 0.78 MAPK1 (0.53) MEN1KMT2ACYP1A2CYP2C9KDM4E
SCHEMBL29788840 0.77 ALDH1A1 (0.65) MEN1KMT2ACYP1A2CYP2C9MAPT
SCHEMBL708243 0.77 KDM4E (0.51) MEN1KMT2ACYP1A2CYP2C9KDM4E
SCHEMBL13166770 0.76 MEN1 (0.49) MEN1KMT2ACYP1A2CYP2C9TP53
SCHEMBL10022389 0.76 NOTUM (0.53) MEN1KMT2ACYP1A2CYP2C9KDM4E
SCHEMBL8865759 0.76 CYP19A1 (0.61) MEN1KMT2AMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200562-B1 DENTAL COMPOSITION FOR DETECTING BACTERIA, KIT OF PARTS AND USE THEREOF 3M INNOVATIVE PROPERTIES CO (US) 2014-04-23 EP claimed
EP-4739669-A1 SODIUM CHANNEL BLOCKERS Novartis AG (CH) 2026-05-13 EP disclosed
US-20250034108-A1 SODIUM CHANNEL BLOCKERS NOVARTIS AG (CH) 2025-01-30 US disclosed
WO-2025011450-A1 SODIUM CHANNEL BLOCKERS NOVARTIS AG (CH) 2025-01-16 WO disclosed
EP-3444238-B1 PROCESS FOR PREPARING DIFLUOROMETHYLENE COMPOUNDS SATO PHARMA (JP) 2021-12-08 EP disclosed
EP-3444238-A2 PROCESS FOR PREPARING DIFLUOROMETHYLENE COMPOUNDS Sato Pharmaceutical Co., Ltd. (JP) 2019-02-20 EP disclosed
EP-2878594-B1 DIFLUOROMETHYLENE COMPOUND SATO PHARMA (JP) 2018-11-28 EP disclosed
CN-107922394-A 3 tetrazole radical benzene, 1,2 disulfonic acid amide derivative as metal beta lactamase restrainer 默沙东公司 2018-04-17 CN disclosed
CN-104662007-B Cystathionine gamma lyase (CSE) inhibitor 索瓦制药公司 2018-03-16 CN disclosed
US-9650380-B2 Difluoromethylene compound SATO PHARMACEUTICAL CO., LTD. (JP) 2017-05-16 US disclosed
US-6136834-A TETRAZOLE PEPTIDES ONO PHARMACEUTICAL CO., LTD. (JP) 2000-10-24 US disclosed
US-6124343-A Substituted phenyl compounds with a substituent having a thienyl ring RHONE-POULENC RORER LIMITED (GB) 2000-09-26 US disclosed
EP-0805802-B1 SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS RHONE POULENC RORER LTD (GB) 2000-08-16 EP disclosed
US-6048893-A Substituted phenyl compounds with a substituent having A 1,3-benzodioxole ring RHONE-POULENC RORER LIMITED (GB) 2000-04-11 US disclosed
EP-0900791-A1 TETRAZOLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 1999-03-10 EP disclosed
CN-1178525-A Substituted phenyl compounds as endothelin antagonists RHONE POULEUC RORER LTD (GB) 1998-04-08 CN disclosed
US-5710153-A INTERLEUKIN CONVERTING ENZYME INHIBITORS ONO PHRAMACEUTICAL CO., LTD. (JP) 1998-01-20 US disclosed
EP-0805802-A1 SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS RHONE-POULENC RORER LIMITED (GB) 1997-11-12 EP disclosed
EP-0761680-A2 Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity ONO PHARMACEUTICAL CO., LTD. (JP) 1997-03-12 EP disclosed
WO-1996022978-A1 SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS RHONE POULENC RORER LIMITED (GB) 1996-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034108-A1 SODIUM CHANNEL BLOCKERS SCN5A, SCN2B, SCN1B MEN1 3531/4885KMT2A 2840/4885CYP1A2 3667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.